ResearcherErasmus MCActive in the last 2 years

Dana A. M. Mustafa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0644-078X; OpenAlex author ID A5071589826. Sources: OpenAlex.

Their work

Papers: 26 (first author 2, last author 6)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 40

Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 6 papers · 2022: 9 papers · 2023: 3 papers · 2024: 6 papers

Papers 26

FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction. Co-author DOI 10.1016/j.ejca.2023.113440 ↗
A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy. Co-author DOI 10.1016/j.neo.2024.100975 ↗
Overexpression of the adhesion signaling pathway is linked to short-term survival in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2023.11.001 ↗
GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery. Last author DOI 10.1016/j.xcrm.2024.101557 ↗
Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer. First author DOI 10.1136/gutjnl-2023-330480 ↗
Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. Co-author DOI 10.1158/1078-0432.ccr-23-4085 ↗
A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejca.2022.12.024 ↗
Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries-Profiling Blood Samples of Pancreatic Ductal Adenocarcinoma Patients. Last author DOI 10.3390/cancers15174349 ↗
Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3. Co-author PMID 37424830 ↗
Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I stud… Co-author DOI 10.1016/j.ejca.2022.03.015 ↗
Fat-Soluble Vitamin Deficiencies and Disruption of the Immune System in Pancreatic Cancer: A Vicious Cycle. Co-author DOI 10.1097/mpa.0000000000002128 ↗
Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients. Co-author DOI 10.3389/fimmu.2022.898498 ↗
Spatial genomics reveals a high number and specific location of B cells in the pancreatic ductal adenocarcinoma microenvironment of long-term survivors. Last author DOI 10.3389/fimmu.2022.995715 ↗
High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2022.827755 ↗
The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation. Co-author DOI 10.3390/biomedicines10030517 ↗
Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancr… Co-author DOI 10.3390/cancers14061377 ↗
Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced P… Co-author DOI 10.3390/cancers14215299 ↗
Immunomodulatory antitumor effect of interferon‑beta combined with gemcitabine in pancreatic cancer. Co-author DOI 10.3892/ijo.2022.5387 ↗
Robust deep learning model for prognostic stratification of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1016/j.isci.2021.103415 ↗
Circulating Immunological Biomarkers: Prognosis of Pancreatic Cancer Patients Reflected by the Immune System. First author DOI 10.1097/mpa.0000000000001862 ↗
Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. Co-author DOI 10.1177/17588359211033704 ↗
Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes. Last author DOI 10.3389/fimmu.2021.649061 ↗
Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in Cancer Patients? Co-author DOI 10.3390/cancers13122896 ↗
Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicente… Co-author DOI 10.3390/ijms222010902 ↗
Serum miR-338-3p and miR-199b-5p are associated with the absolute neutrophil count in patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.cca.2020.03.005 ↗
Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers11010093 ↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.